Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Yeap Ltd. maintains a focused patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action across its active filings. This workload is assigned to 1 distinct examiner and 1 distinct art unit, indicating a concentrated prosecution environment. The presence of a single art unit suggests that the company's current intellectual property efforts are confined to a specific technical niche within the Biotechnology & Pharmaceuticals sector.
The busiest examiner for this portfolio is FERNANDEZ, SUSAN EMILY, who is currently handling 1 pending office action. This individual represents the entirety of the company's current pending interactions with the patent office. Practitioners can expect a streamlined communication channel given the lack of diversity in art units and examiners assigned to these matters. Because FERNANDEZ, SUSAN EMILY is the only examiner involved, the prosecution strategy for the portfolio is currently dependent on the specific tendencies of this individual.
The portfolio shows a low volume of active negotiation with the patent office. The alignment of a single examiner and art unit for the current matter ensures that all legal correspondence is centralized. This centralization may allow for a more consistent approach to patent prosecution compared to portfolios spread across multiple examiners or art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FERNANDEZ, SUSAN EMILY | 1 | 52.3% | +60.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278242 | MICROORGANISM-DERIVED MATERIAL AND METHODS FOR PRODUCING SAME | FERNANDEZ, SUSAN EMILY | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18278242 | MICROORGANISM-DERIVED MATERIAL AND METHODS FOR PRODUCING SAME | FERNANDEZ, SUSAN EMILY | 1651 | §103 | Final Rejection | — | Pending | Aug 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYeap Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Susan Emily Fernandez has the most, with 1 of Yeap Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
